Recombinant CD40-ligand
Also known as: CD154, CD40 Ligand recombinant, CD40L, rCD154, rCD40L, TNFSF5, TRAP (TNF-Related Activation Protein)
Source Recombinant CD40-ligand at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Recombinant soluble CD40‑ligand (CD154) is a biologic protein used experimentally to stimulate CD40‑mediated immune responses, investigated as a vaccine adjuvant and cancer immunotherapy.
Mechanism of Action
Soluble CD40 ligand binds CD40 on antigen‑presenting cells, triggering NF‑κB activation and enhancing immune cell activation
Routes of Administration
Goals & Uses
- Vaccine adjuvantVaccinologyModerate
- Platelet activation researchHematology / ResearchModerate
- Cancer immunotherapyOncologyModerate
- B cell immunodeficiency (Hyper-IgM syndrome)Immunology / Rare DiseaseLow
Contraindications
- History of thromboembolic eventsHematologicalHigh
- Severe cardiovascular diseaseCardiovascularHigh
- Active autoimmune diseaseAutoimmunityModerate
Adverse Effects
- Cytokine release syndromeImmunologicUnknownSystemic inflammatory response from immune activation
- Thromboembolic events (DVT, PE, arterial thrombosis)Hematological / VascularUncommon
- Flu‑like symptomsSystemicUnknown
- Injection site reactionsLocalCommon
- Fever / flu-like symptomsSystemicCommon
- Anti-drug antibody formationImmunologicalUncommon
- Cytokine release / inflammatory responseImmunologicalUncommon
Drug Interactions
- Antiplatelet agents (aspirin, clopidogrel)Low
- Immunosuppressive agents (e.g., corticosteroids, cyclosporine)Moderate
- Anticoagulants (warfarin, heparin, direct oral anticoagulants)Moderate
Population Constraints
- Pediatric patientsAgeRelative
- Patients with hypercoagulable statesHematologicalAbsolute
- Pregnant or breastfeeding womenReproductiveAbsolute
- Elderly patientsAgeRelative
- Pregnant womenReproductiveRelative
Regulatory Status
- European UnionInvestigationalUnder clinical investigation in Europe
- United StatesInvestigationalInvestigational biologic; not FDA‑approved
- United KingdomInvestigationalNo MHRA approval. Follows similar status to EU; no approved therapeutic use.
No approved indication in any major jurisdiction. Early-phase clinical trials were halted or suspended due to serious thromboembolic events. Remains primarily a research-stage molecule. Some investigational use continues in ex vivo settings and as a vaccine adjuvant component.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Recombinant CD40-ligand?
Recombinant soluble CD40‑ligand (CD154) is a biologic protein used experimentally to stimulate CD40‑mediated immune responses, investigated as a vaccine adjuvant and cancer immunotherapy.
What is Recombinant CD40-ligand used for?
Recombinant CD40-ligand is educationally associated with: Vaccine adjuvant, Platelet activation research, Cancer immunotherapy, B cell immunodeficiency (Hyper-IgM syndrome). Educational only — not medical advice.
How is Recombinant CD40-ligand administered?
Recorded routes of administration: Intratumoral, Intravenous, Subcutaneous.
What are the potential side effects of Recombinant CD40-ligand?
Reported adverse effects include: Cytokine release syndrome, Thromboembolic events (DVT, PE, arterial thrombosis), Flu‑like symptoms, Injection site reactions, Fever / flu-like symptoms, Anti-drug antibody formation, Cytokine release / inflammatory response. This list is not exhaustive — consult a qualified clinician.
Who should avoid Recombinant CD40-ligand?
Recorded contraindications: History of thromboembolic events, Severe cardiovascular disease, Active autoimmune disease. Consult a qualified clinician before use.